Grace Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2024 · Filed Feb 13, 2025
GRCE$1.86-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine months ended | ||
|---|---|---|
| December 31, 2024 | December 31, 2023 | |
| (Expressed in thousands) | $ | $ |
| Cash flows used in operating activities: | ||
| Net loss | (10,204) | (9,687) |
| Adjustments: | ||
| Depreciation expense | 5 | 10 |
| Gain on sale of equipment | — | (26) |
| Stock-based compensation | 600 | 684 |
| Change in fair value of derivative warrant liabilities | (578) | 1,701 |
| Deferred income tax benefit | (2,181) | (943) |
| Changes in operating assets and liabilities: | ||
| Receivables | 421 | (157) |
| Prepaid expenses | (300) | (213) |
| Trade and other payables | 287 | (1,591) |
| Operating lease right of use asset | — | (23) |
| Net cash used in operating activities | (11,950) | (10,245) |
| Cash flows from investing activities: | ||
| Proceeds from sale of equipment | — | 110 |
| Maturity of short-term investments | 15 | — |
| Purchase of short-term investments | (15) | (6,554) |
| Net cash used in investing activities | — | (6,444) |
| Cash flows from financing activities: | ||
| Net proceeds from issuance of common stock and warrants from private placement | — | 7,338 |
| Proceeds from issuance of common stock from exercise of stock options | — | 21 |
| Net cash provided by financing activities | — | 7,359 |
| Net decrease in cash and cash equivalents | (11,950) | (9,330) |
| Cash and cash equivalents, beginning of period | 23,005 | 27,875 |
| Cash and cash equivalents, end of period | 11,055 | 18,545 |
| Cash and cash equivalents are comprised of: | ||
| Cash | 836 | 2,060 |
| Cash equivalents | 10,219 | 16,485 |
(Formerly ACASTI PHARMA, INC.)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.